Archived Newsletters
-
06.30.25 -- STREAM Edition: When Outsourcing, Take Advantage Of Each Other's Strengths
6/30/2025
06/30/25 Outsourced Pharma Newsletter
-
06.30.25 -- Lonza Bets The House On Biologics. What's It Mean For You?
6/30/2025
06/30/25 Outsourced Pharma Newsletter
-
06.27.25 -- How A Biotech Navigates The CDMO Frenzy For GLP-1 Services
6/27/2025
06/27/25 Outsourced Pharma Newsletter
-
06.26.25 -- Outsourcing GLP-1 Programs: Is There Capacity For Biotechs?
6/26/2025
06/26/25 Outsourced Pharma Newsletter
-
06.25.25 -- Technical Approaches To Strengthen Your Drug Product Development
6/25/2025
06/25/25 Outsourced Pharma Newsletter
-
06.25.25 -- Streamline Your Scale-Up: Key Strategies For Biologics Manufacturing Success
6/25/2025
06/25/25 Outsourced Pharma Newsletter
-
06.25.25 -- Early-Phase Formulation Done Right: An Expert Analysis
6/25/2025
06/25/25 Outsourced Pharma Newsletter
-
06.24.25 -- A Psychedelic Path To CDMO Selection?
6/24/2025
06/24/25 Outsourced Pharma Newsletter
-
06.23.25 -- STREAM Edition: Drug Development Outsourcing: The Devil Is In The Details
6/23/2025
06/23/25 Outsourced Pharma Newsletter
-
06.23.25 -- Is An Outsourced BD Model Gaining Traction At CDMOs?
6/23/2025
06/23/25 Outsourced Pharma Newsletter